Please wait a minute...
J Zhejiang Univ (Med Sci)  2020, Vol. 49 Issue (2): 245-248    DOI: 10.3785/j.issn.1008-9292.2020.03.12
    
Management of a colon cancer patient complicated with COVID-19
YE Ziqi(),HONG Yun,WU Xiuhua,HONG Dongsheng,ZHANG Yanfang,DONG Xihao,RAO Yuefeng*(),LU Xiaoyang*()
Department of Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Download: HTML( 30 )   PDF(1028KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Objective: To explore the feasibility of radical resection for cancer patients complicated with coronavirus disease 2019 (COVID-19). Methods: The management and clinical outcome of a sigmoid cancer patient with COVID-19 were analyzed. Results: The inflammation indicators and fever of this patient were effectively controlled and the lung lesions remained stable after active anti-viral treatment, then the radical colorectomy was performed after the viral negative conversion for twice. Conclusion: The case indicates that radical resection can be performed in SARS-CoV-2 patients with twice-negative SARS-CoV-2 nucleic acid testing results.



Key wordsCoronavirus disease 2019      Severe acute respiratory syndrome coronavirus 2      Novel coronavirus pneumonia      Colon cancer      Radical resection      Timing of treatment     
Received: 04 March 2020      Published: 27 March 2020
CLC:  R730.5  
Corresponding Authors: RAO Yuefeng,LU Xiaoyang     E-mail: ziqiye@zju.edu.cn;raoyf@zju.edu.cn;luxiaoyang@zju.edu.cn
Cite this article:

YE Ziqi,HONG Yun,WU Xiuhua,HONG Dongsheng,ZHANG Yanfang,DONG Xihao,RAO Yuefeng,LU Xiaoyang. Management of a colon cancer patient complicated with COVID-19. J Zhejiang Univ (Med Sci), 2020, 49(2): 245-248.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2020.03.12     OR     http://www.zjujournals.com/med/Y2020/V49/I2/245


一例肿瘤合并2019冠状病毒病(COVID-19)患者的治疗决策分析

目的: 探讨亟待进行肿瘤根治术的患者合并2019冠状病毒病(COVID-19)后如何选择手术治疗时机。方法: 详细分析1例乙状结肠癌合并COVID-19患者的治疗过程,以及该患者在病毒两次转阴后进行根治性手术后的恢复情况。结果: 患者术后恢复良好,炎症指标、发热等临床表现改善,肺部病灶也维持稳定。结论: 对于亟待进行肿瘤根治术且合并COVID-19的患者,在符合病毒核酸检测两次阴性之后进行肿瘤根治术是可行的。


关键词: 2019冠状病毒病,  严重急性呼吸综合征冠状病毒2,  新型冠状病毒肺炎,  结肠癌,  根治性手术,  治疗时机 
检测时间 白细胞计数
(×109/L)
中性粒细胞计数
(×109/L)
血红蛋白
(g/L)
淋巴细胞计数
(×109/L)
血小板计数
(×109/L)
C反应蛋白
(mg/L)
降钙素原
(ng/mL)
丙氨酸转氨酶
(U/L)
天冬氨酸转氨酶
(U/L)
碱性磷酸酶
(U/L)
总胆红素
(μmol/L)
白蛋白
(g/L)
肌酐
(μmol/L)
术前 3.6 2.9 84 0.4 66 70 0.18 33 22 66 43.8 34.7 43
术后1 d 4.2 3.4 108 0.9 49 107 0.37 21 17 61 30.0 31.6 48
术后3 d 11.8 10.1 99 2.1 75 95 0.23 31 35 88 23.7 31.7 43
术后6 d 6.6 5.0 117 1.6 67 86 0.19 17 18 96 27.7 30.3 45
Tab 1 Laboratory examination of a COVID-19 patient before and after sigmoid colon cancer radical resection
[1]   KAMBOJ M , SEPKOWITZ K A . Nosocomial infections in patients with cancer[J]. Lancet Oncol, 2009, 10 (6): 589- 597
doi: 10.1016/S1470-2045(09)70069-5
[2]   LI J Y , DUAN X F , WANG L P et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer[J]. J Immunol Res, 2014, 2014 286170
doi: 10.1155/2014/286170
[3]   LONGBOTTOM E R , TORRANCE H D , OWEN H C et al. Features of postoperative immune suppression are reversible with interferon gamma and independent of interleukin-6 pathways[J]. Ann Surg, 2016, 264 (2): 370- 377
doi: 10.1097/SLA.0000000000001484
[4]   SICA A , MASSAROTTI M . Myeloid suppressor cells in cancer and autoimmunity[J]. J Autoimmun, 2017, 85 117- 125
doi: 10.1016/j.jaut.2017.07.010
[5]   LIANG W , GUAN W , CHEN R et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China[J]. Lancet Oncol, 2020, 21 (3): 335- 337
doi: 10.1016/S1470-2045(20)30096-6
[6]   中华人民共和国国家卫生健康委员会办公厅, 国家中医药管理局办公室.新型冠状病毒感染的肺炎诊疗方案(试行第七版)[A/OL].国卫办医函〔2020〕184号.(2020-03-03)[2020-03-10].http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
General Office of National Health Commission of the People's Republic of China, Office of National Administration of Traditional Chinese Medicine. Diagnosis and treatment of novel coronavirus pneumonia (trial version 7)[A/OL]. No.184〔2020〕 of the General Office of the National Health Commission. (2020-03-03)[2020-03-10]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml. (in Chinese)
[7]   HUANG C , WANG Y , LI X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395 (10223): 497- 506
doi: 10.1016/S0140-6736(20)30183-5
[8]   WANG D, HU B, HU C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J/OL]. JAMA, 2020: e201585. DOI: 10.1001/jama.2020.1585.
[9]   HEINEMANN V , VON WEIKERSTHAL L F , DECKER T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer(FIRE-3): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2014, 15 (10): 1065- 1075
doi: 10.1016/S1470-2045(14)70330-4
[10]   黄耿文 . 新型冠状病毒肺炎疫情下实施普通外科手术的思考和建议[J]. 中华普通外科杂志, 2020, 29 (2): 127- 130
HUANG Gengwen . Thoughts and advices on performing procedures in general surgery during the outbreak of novel coronavirus pneumonia[J]. Chinese Journal of General Surgery, 2020, 29 (2): 127- 130
doi: 10.7659/j.issn.1005-6947.2020.02.001
[1] WANG Jincheng,LIU Jinpeng,WANG Yuanyuan,LIU Wei,CHEN Xiaoqun,SUN Chao,SHEN Xiaoyong,WANG Qidong,WU Yaping,LIANG Wenjie,RUAN Lingxiang. Dynamic changes of chest CT imaging in patients with COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 191-197.
[2] ZHANG Xiaoyan, SUN Wei, SHANG Shiqiang, MAO Jianhua, FU Junfen, SHU Qiang, JIANG Kewen. Principles and suggestions on biosafety protection of biological specimen preservation during prevalence of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 170-177.
[3] CAO Shengli,FENG Peihua,SHI Pengpeng. Study on the epidemic development of COVID-19 in Hubei province by a modified SEIR model[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 178-184.
[4] CHEN Jun,LIU Danping,LIU Li,LIU Ping,XU Qingnian,XIA Lu,LING Yun,HUANG Dan,SONG Shuli,ZHANG Dandan,QIAN Zhiping,LI Tao,SHEN Yinzhong,LU Hongzhou. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 215-219.
[5] CHEN Zhimin,FU Junfen,SHU Qiang,WANG Wei,CHEN Yinghu,HUA Chunzhen,LI Fubang,LIN Ru,TANG Lanfang,WANG Tianlin,WANG Yingshuo,XU Weize,YANG Zihao,YE Sheng,YUAN Tianming,ZHANG Chenmei,ZHANG Yuanyuan. Diagnosis and treatment recommendation for pediatric COVID-19 (the second edition)[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 139-146.
[6] XU Kaijin,CAI Hongliu,SHEN Yihong,NI Qin,CHEN Yu,HU Shaohua,LI Jianping,WANG Huafen,YU Liang,HUANG He,QIU Yunqing,WEI Guoqing,FANG Qiang,ZHOU Jianying,SHENG Jifang,LIANG Tingbo,LI Lanjuan. Management of COVID-19: the Zhejiang experience[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 147-157.
[7] JIANG Saiping,LI Lu,RU Renping,ZHANG Chunhong,RAO Yuefeng,LIN Bin,WANG Rongrong,CHEN Na,WANG Xiaojuan,CAI Hongliu,SHENG Jifang,ZHOU Jianying,LU Xiaoyang,QIU Yunqing. Pharmaceutical care for severe and critically ill patients with COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 158-169.
[8] LI Xin,DAI Tian,WANG Hong,SHI Junnian,YUAN Wei,LI Jing,CHEN Lijun,ZHANG Tianming,ZHANG Shanshan,KONG Yan,YUE Ning,SHI Hui,HE Yuping,HU Huifang,LIU Furong,YANG Caixia. Clinical analysis of suspected COVID-19 patients with anxiety and depression[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 203-208.
[9] LUO Song,YANG Lijuan,WANG Chun,LIU Chuanmiao,LI Dianming. Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 227-231.
[10] HONG Dongsheng,NI Jian,SHAN Wenya,LI Lu,HU Xi,YANG Hongyu,ZHAO Qingwei,ZHANG Xingguo. Establishment of a rapid identification of adverse drug reaction program in R language implementation based on monitoring data[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 253-259.
[11] ZHONG Qi,LI Zhi,SHEN Xiaoyong,XU Kaijin,SHEN Yihong,FANG Qiang,CHEN Feng,LIANG Tingbo. CT imaging features of patients with different clinical types of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 198-202.
[12] KANG Xianhui,ZHANG Rong,HE Huiliang,YAO Yongxing,ZHENG Yueying,WEN Xiaohong,ZHU Shengmei. Anesthesia management in cesarean section for patient with COVID-19: a case report[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 249-252.
[13] CHEN Xu,LI Yang,WANG Jinxi,CAI Hongliu,CAO Hongcui,SHENG Jifang. Pregnant women complicated with COVID-19: a clinical analysis of 3 cases[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 240-244.
[14] SHEN Lihua,HUANG Fei,CHEN Xiang,XIONG Zuan,YANG Xiaoyu,LI Hui,CHENG Feng,GUO Jian,GONG Guofu. Diagnostic efficacy of three test kits for SARS-CoV-2 nucleic acid detection[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 185-190.
[15] ZHAGN Sheng,LI Danping,CHEN Huazhong,ZHENG Dan,ZHOU Yiping,CHEN Baoguo,SHI Weiwu,LIN Ronghai. Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 220-226.